Efficacy and Safety Analysis of Botox Application and Iatrogenic Botulism: Panacea or Peril?


Cite item

Full Text

Abstract

Clostridium botulinum toxin-A (BoNT-A) creates temporary paralysis in the muscles by acting on the muscle-nerve junction. It is injected into the mimic muscles when a decrease in the movements of the mimic muscles is desired. Despite many favorable applications, the use of BoNT-A is not without drawbacks. Although there is no expected serious side effect on health in BoNT-A treatments, various problems can be encountered in patients treated for aesthetic purposes. Botulism is a rare but potentially life-threatening syndrome, which is caused by the toxin produced by the bacterium Clostridium botulinum, which acts on the nervous system, vegetative forms of C. botulinum can only survive in anaerobic conditions, while spore forms are common in nature and can withstand harsh conditions. Botulism can stem from bacterial spores which release toxin in the body; in the form of enteric botulism, and wound botulism. The cases that develop ‘iatrogenic botulism’ after such procedures are usually those receiving high-dose toxin for therapeutic purposes. The treatment of botulism mainly consists of anti-toxin therapy and, if necessary, intensive care to prevent organ failures, including respiratory support. This article aims to cover all these issues related to botulism and other adverse outcomes related to BoNT-A injection in light of the most recent literature.

About the authors

Ozgur Karcioglu

Department of Emergency Medicine, Taksim Education and Research Hospital, University of Health Sciences

Author for correspondence.
Email: info@benthamscience.net

Canan Akman

Department of Emergency Medicine, Canakkale Onsekiz Mart University

Email: info@benthamscience.net

Ilknur Atnis

Department of Emergency Medicine, Niğde Omer Halisdemir Education and Research Hospital, University of Health Sciences

Email: info@benthamscience.net

References

  1. Jewell ML, Monheit GD. An overview of clinical trial data on a new formulation of botulinum neurotoxin type A. Aesthet Surg J 2009; 29(S6): S31-3. doi: 10.1016/j.asj.2009.09.011 PMID: 19945002
  2. Berry MG, Stanek JJ. Botulinum neurotoxin A: A review. J Plast Reconstr Aesthet Surg 2012; 65(10): 1283-91. doi: 10.1016/j.bjps.2012.04.016 PMID: 22552262
  3. Pasricha TS, Pasricha PJ. Botulinum toxin injection for treatment of gastroparesis. Gastrointest Endosc Clin N Am 2019; 29(1): 97-106. doi: 10.1016/j.giec.2018.08.007 PMID: 30396531
  4. Erbguth FJ. Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov Disord 2004; 19(S8): S2-6. doi: 10.1002/mds.20003 PMID: 15027048
  5. Carr WW, Jain N, Sublett JW. Immunogenicity of botulinum toxin formulations: Potential therapeutic implications. Adv Ther 2021; 38(10): 5046-64. doi: 10.1007/s12325-021-01882-9 PMID: 34515975
  6. Lewandowski M, Świerczewska Z, Barańska-Rybak W. Off-label use of botulinum toxin in dermatology-current state of the art. Molecules 2022; 27(10): 3143. doi: 10.3390/molecules27103143 PMID: 35630620
  7. Phan K, Younessi S, Dubin D, Lin MJ, Khorasani H. Emerging OFF-LABEL esthetic uses of botulinum toxin in dermatology. Dermatol Ther 2022; 35(1): e15205. doi: 10.1111/dth.15205 PMID: 34792262
  8. Hafeez MU, Moore M, Hafeez K, Jankovic J. Exploring the role of botulinum toxin in critical care. Expert Rev Neurother 2021; 21(8): 881-94. doi: 10.1080/14737175.2021.1958678 PMID: 34281468
  9. American Society for Aesthetic Plastic Surgery Website. Cosmetic Surgery National Data Bank Statistics. 2008. Available from: http://www.surgery.org/sites/default/files/2008stats.pdf
  10. Nestor MS, Fischer D, Arnold D. "Masking" our emotions: Botulinum toxin, facial expression, and well-being in the age of COVID-19. J Cosmet Dermatol 2020; 19(9): 2154-60. doi: 10.1111/jocd.13569 PMID: 32592268
  11. Wortzman MS, Pickett A. The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use. Aesthet Surg J 2009; 29(S6): S34-42. doi: 10.1016/j.asj.2009.09.014 PMID: 19945003
  12. Pickett A. Dysport®: Pharmacological properties and factors that influence toxin action. Toxicon 2009; 54(5): 683-9. doi: 10.1016/j.toxicon.2009.03.020 PMID: 19332087
  13. Hexsel C, Hexsel D, Porto MD, Schilling J, Siega C. Botulinum toxin type A for aging face and aesthetic uses. Dermatol Ther 2011; 24(1): 54-61. doi: 10.1111/j.1529-8019.2010.01378.x PMID: 21276158
  14. Borodic GE, Ferrante R, Pearce LB, Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum a toxin injections. Mov Disord 1994; 9(1): 31-9. doi: 10.1002/mds.870090106 PMID: 8139603
  15. Koriazova LK, Montal M. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol 2003; 10: 13e8. doi: 10.1038/nsb879
  16. del Boz J, Padilla-España L, Segura-Palacios JM. Botulinum toxin injection technique for axillary hyperhidrosis. Actas Dermosifiliogr 2014; 105(5): 517-8. doi: 10.1016/j.adengl.2014.04.011 PMID: 24468624
  17. Iannitti T, Di Cerbo A, Aspiro A, Palmieri B. A preliminary study of painless and effective transdermal botulinum toxin A delivery by jet nebulization for treatment of primary hyperhidrosis. Drug Des Devel Ther 2014; 8: 931-5. doi: 10.2147/DDDT.S60389 PMID: 25075176
  18. Martina E, Diotallevi F, Radi G, Campanati A, Offidani A. Therapeutic use of botulinum neurotoxins in dermatology: Systematic review. Toxins 2021; 13(2): 120. doi: 10.3390/toxins13020120 PMID: 33562846
  19. Lu B. The destructive effect of botulinum neurotoxins on the SNARE protein: SNAP-25 and synaptic membrane fusion. PeerJ 2015; 3: e1065. doi: 10.7717/peerj.1065 PMID: 26157630
  20. Fujimoto T. Pathophysiology and treatment of hyperhidrosis. Curr Probl Dermatol 2016; 51: 86-93. doi: 10.1159/000446786 PMID: 27584967
  21. BOTOX® (onabotulinumtoxinA) for injection, for intramuscular,intradetrusor, or intradermal use. 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103000s5320lbl.pdf
  22. Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of DysportR vs. BotoxR in primary palmar hyperhidrosis. Br J Dermatol 2003; 149(5): 1041-5. doi: 10.1111/j.1365-2133.2003.05620.x PMID: 14632812
  23. Pérez-Bernal AM, Avalos-Peralta P, Moreno-Ramírez D, Camacho F. Treatment of palmar hyperhidrosis with botulinum toxin type A: 44 months of experience. J Cosmet Dermatol 2005; 4(3): 163-6. doi: 10.1111/j.1473-2165.2005.00304.x PMID: 17129260
  24. Kim WO, Kil HK, Yoon KB, Noh KU. Botulinum toxin. Dermatol Surg 2009; 35(5): 833-8. doi: 10.1111/j.1524-4725.2009.01140.x PMID: 19389096
  25. Haider A, Solish N. Focal hyperhidrosis: Diagnosis and management. CMAJ 2005; 172(1): 69-75. doi: 10.1503/cmaj.1040708 PMID: 15632408
  26. Komericki P, Ardjomand N. Hyperhidrosis of face and scalp: Repeated successful treatment with botulinum toxin type A. Indian J Dermatol Venereol Leprol 2012; 78(2): 201-2. doi: 10.4103/0378-6323.93647 PMID: 22421660
  27. BOTOX (onabotulinumtoxinA). Irvine, California: Allergan, Inc 2021.
  28. Bjerkhoel A, Trobbe O. Frey’s syndrome: Treatment with botulinum toxin. J Laryngol Otol 1997; 111(9): 839-44. doi: 10.1017/S0022215100138769 PMID: 9373550
  29. Fedorowicz Z, van Zuuren EJ, Schoones J. Botulinum toxin for masseter hypertrophy. Cochrane Database Syst Rev 2013; 2013(9): CD007510. PMID: 24018587
  30. Lowe N, Naumann M, Eadie N. Treatment of hyperhidrosis with Botox (onabotulinumtoxinA): Development, insights, and impact. Medicine 2023; 102(S1): e32764. doi: 10.1097/MD.0000000000032764 PMID: 37499084
  31. Nattkemper LA, Vander Does A, Stull CM, et al. Prolonged antipruritic effect of botulinum toxin type A on cowhage-induced itch: A randomized, single-blind, placebo-controlled trial. Acta Derm Venereol 2023; 103: adv6581. doi: 10.2340/actadv.v103.6581 PMID: 37584094
  32. Huang SH, Wu KW, Lo JJ, Wu SH. Synergic effect of botulinum toxin type A and triamcinolone alleviates scar pruritus by modulating epidermal hyperinnervation: A preliminary report. Aesthet Surg J 2021; 41(11): NP1721-31. doi: 10.1093/asj/sjab105 PMID: 33662123
  33. Cakir C, Oguz Idiz U, Aydin I, Firat D, İbrahim Ulusoy A, Yazici P. Comparison of the effectiveness of two treatment modalities for chronic anal fissure: Botox versus sphincterotomy. Turk J Surg 2020; 36(3): 264-70. doi: 10.47717/turkjsurg.2020.4492 PMID: 33778381
  34. Li TT, Liu ZY, Xiong L, Zhang ZW. Clinical efficacy of botulinum toxin type A in the treatment of fasciitis pain: A systematic review and meta-analysis. Medicine 2023; 102(30): e34461. doi: 10.1097/MD.0000000000034461 PMID: 37505140
  35. Esquenazi A, Jost WH, Turkel CC, Wein T, Dimitrova R. Treatment of adult spasticity with Botox (onabotulinumtoxinA): Development, insights, and impact. Medicine 2023; 102(S1): e32376. doi: 10.1097/MD.0000000000032376 PMID: 37499086
  36. Jankovic J, Tsui J, Brin MF. Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact. Medicine 2023; 102(S1): e32403. doi: 10.1097/MD.0000000000032403 PMID: 37499081
  37. Turkel CC, Aurora S, Diener HC, et al. Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact. Medicine 2023; 102(S1): e32600. doi: 10.1097/MD.0000000000032600 PMID: 37499085
  38. Cernuda-Morollón E, Ramón C, Martínez-Camblor P, Serrano-Pertierra E, Larrosa D, Pascual J. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain 2015; 156(5): 820-4. doi: 10.1097/j.pain.0000000000000119 PMID: 25735000
  39. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Neurology 2016; 86(19): 1818-26. doi: 10.1212/WNL.0000000000002560 PMID: 27164716
  40. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30(7): 793-803. doi: 10.1177/0333102410364676 PMID: 20647170
  41. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30(7): 804-14. doi: 10.1177/0333102410364677 PMID: 20647171
  42. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000; 38(2): 245-58. doi: 10.1016/S0041-0101(99)00153-1 PMID: 10665805
  43. Herd CP, Tomlinson CL, Rick C, et al. Botulinum toxins for the prevention of migraine in adults. Cochrane Libr 2018; 2018(6): CD011616. doi: 10.1002/14651858.CD011616.pub2 PMID: 29939406
  44. Nitti V, Haag-Molkenteller C, Kennelly M, Chancellor M, Jenkins B, Schurch B. Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact. Medicine (Baltimore) 2023; 102(S1): e32377. doi: 10.1097/MD.0000000000032377 PMID: 37499088
  45. Przydacz M, Golabek T, Chłosta P. How to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxinA. Adv Clin Exp Med 2019; 28(4): 555-67. doi: 10.17219/acem/90764 PMID: 30729759
  46. Jankovic J, Carruthers J, Naumann M, et al. Neutralizing antibody formation with OnabotulinumtoxinA (BOTOX®) treatment from global registration studies across multiple indications: A meta-analysis. Toxins 2023; 15(5): 342. doi: 10.3390/toxins15050342 PMID: 37235376
  47. Ho WWS, Albrecht P, Calderon PE, et al. Emerging trends in botulinum neurotoxin a resistance: An international multidisciplinary review and consensus. Plast Reconstr Surg Glob Open 2022; 10(6): e4407. doi: 10.1097/GOX.0000000000004407 PMID: 35747253
  48. Münchau A, Bhatia KP. Regular review: Uses of botulinum toxin injection in medicine today. BMJ 2000; 320(7228): 161-5. doi: 10.1136/bmj.320.7228.161 PMID: 10634738
  49. Allergan Pharmaceuticals Ireland a subsidiary of: Allergan, Inc Prescribing Information for BOTOX. Allergan USA, Inc: Madison, NJ 07940 ©2022 Allergan 2022.
  50. Naik PP. Utilities of botulinum toxins in dermatology and cosmetology. Clin Cosmet Investig Dermatol 2021; 14: 1319-30. doi: 10.2147/CCID.S332247 PMID: 34584436
  51. Li X, Sui C, Xia X, Chen X. Efficacy and safety of botulinum toxin type A for treatment of glabellar lines: A network meta-analysis of randomized controlled trials. Aesthetic Plast Surg 2023; 47(1): 365-77. doi: 10.1007/s00266-022-03018-y PMID: 36097079
  52. Cohen JL, Scuderi N. Safety and patient satisfaction of abobotulinumtoxina for aesthetic use: A systematic review. Aesthet Surg J 2017; 37(S1): S32-44. doi: 10.1093/asj/sjx010 PMID: 28388721
  53. Wu Y, Fang F, Lai W, et al. Efficacy and safety of abobotulinumtoxina for the treatment of glabellar lines in chinese patients: A pivotal, phase 3, randomized, double-blind and open-label phase study. Aesthetic Plast Surg 2023; 47(1): 351-64. doi: 10.1007/s00266-022-03164-3 PMID: 36536093
  54. Dessy LA, Fallico N, Mazzocchi M, Scuderi N. Botulinum toxin for glabellar lines: A review of the efficacy and safety of currently available products. Am J Clin Dermatol 2011; 12(6): 1. doi: 10.2165/11592100-000000000-00000 PMID: 21877763
  55. Coté TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: Adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 2005; 53(3): 407-15. doi: 10.1016/j.jaad.2005.06.011 PMID: 16112345
  56. Kawashima M, Harii K, Horiuchi Y, et al. Safety, efficacy, and patient satisfaction with onabotulinumtoxina for the treatment of upper facial lines in japanese subjects. Dermatol Surg 2020; 46(4): 483-90. doi: 10.1097/DSS.0000000000002143 PMID: 31517663
  57. Hexsel D, Brum C, Porto MD, et al. Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy. J Drugs Dermatol 2013; 12(12): 1356-62. PMID: 24301236
  58. Kestemont P, Hilton S, Andriopoulos B, et al. Long-term efficacy and safety of liquid abobotulinumtoxina formulation for moderate-to-severe glabellar lines: A phase III, double-blind, randomized, placebo-controlled and open-label study. Aesthet Surg J 2022; 42(3): 301-13. doi: 10.1093/asj/sjab329 PMID: 34472596
  59. Chertow DS, Tan ET, Maslanka SE, et al. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA 2006; 296(20): 2476-9. doi: 10.1001/jama.296.20.2476 PMID: 17119144
  60. Gadient PM, Smith JH, Ryan SJ. Herpes zoster ophthalmicus following onabotulinumtoxinA administration for chronic migraine: A case report and literature review. Cephalalgia 2015; 35(5): 443-8. doi: 10.1177/0333102414544974 PMID: 25135654
  61. Wang C, Zhao J, Gao F, Jia M, Hu L, Gao C. The efficacy and safety of intra-articular botulinum toxin type A injection for knee osteoarthritis: A meta-analysis of randomized controlled trials. Toxicon 2023; 224: 107026. doi: 10.1016/j.toxicon.2023.107026 PMID: 36640812
  62. Patil A, Kassir M, Wollina U, Goldust M. Neue Botulinumtoxine in der ästhetischen Dermatologie: Ein umfassender Überblick (New botulinum toxins for aesthetic dermatology: A comprehensive review). Hautarzt 2021; 72(5): 393-402. doi: 10.1007/s00105-021-04801-9
  63. Corasaniti MT, Bagetta G, Nicotera P, et al. Safety of onabotulinumtoxin a in chronic migraine: A systematic review and meta-analysis of randomized clinical trials. Toxins 2023; 15(5): 332. doi: 10.3390/toxins15050332 PMID: 37235366
  64. Li M, Goldberger BA, Hopkins C. Fatal case of BOTOX-related anaphylaxis. J Forensic Sci 2005; 50: 169e72.
  65. Botulism. Available from: https://web.archive.org/web/20170218070333/https://www.britannica.com/science/Botulism
  66. Setlow P. I will survive: DNA protection in bacterial spores. Trends Microbiol 2007; 15: 172e80.
  67. Karsen H, Ceylan MR, Bayındır H, Akdeniz H. Foodborne botulism in Turkey, 1983 to 2017. Infect Dis 2019; 51(2): 91-6. doi: 10.1080/23744235.2018.1524582 PMID: 30663916
  68. Bai L, Peng X, Liu Y, et al. Clinical analysis of 86 botulism cases caused by cosmetic injection of botulinum toxin (BoNT). Medicine 2018; 97(34): e10659. doi: 10.1097/MD.0000000000010659 PMID: 30142749
  69. Nassif AD, Boggio RF, Espicalsky S, Faria GEL. High precision use of botulinum toxin type A (BONT-A) in aesthetics based on muscle atrophy, is muscular architecture reprogramming a possibility? A systematic review of literature on muscle atrophy after BoNT-A injections. Toxins 2022; 14(2): 81. doi: 10.3390/toxins14020081 PMID: 35202109
  70. Brennan C. Update on neurotoxins for facial rejuvenation: What they are, how they work, and how to effectively and safely use them. Plast Surg Nurs 2015; 35(2): 69-75. doi: 10.1097/PSN.0000000000000091 PMID: 26020471
  71. Charatan F. Germs: Biological weapons and America's secret war. BMJ 2001; 323(7321): 1135.
  72. Miller J, Engelberg S, Broad W. Germs: Biological weapons and America's secret war. 2001; 382.
  73. Arnon SS, Schechter R, Inglesby TV, et al. Working Group on Civilian Biodefense. Botulinum toxin as a biological weapon: Medical and public health management. JAMA 2001; 285(8): 1059-70. Erratum in JAMA 2001, 285, 2081 doi: 10.1001/jama.285.8.1059 PMID: 11209178
  74. Lin L, Olson ME, Eubanks LM, Janda KD. Strategies to counteract botulinum neurotoxin a: Nature’s deadliest biomolecule. Acc Chem Res 2019; 52(8): 2322-31. doi: 10.1021/acs.accounts.9b00261 PMID: 31322847
  75. Ahsanuddin S, Roy S, Nasser W, Povolotskiy R, Paskhover B. Adverse events associated with botox as reported in a food and drug administration database. Aesthetic Plast Surg 2021; 45(3): 1201-9. doi: 10.1007/s00266-020-02027-z PMID: 33128076
  76. Omprakash HM, Rajendran SC. Botulinum toxin deaths: What is the fact? J Cutan Aesthet Surg 2008; 1(2): 95-7. doi: 10.4103/0974-2077.44169 PMID: 20300354
  77. Tugnoli V, Eleopra R, Quatrale R, Capone JG, Sensi M, Gastaldo E. Botulism-like syndrome after botulinum toxin type A injections for focal hyperhidrosis. Br J Dermatol 2002; 147(4): 808-9. doi: 10.1046/j.1365-2133.2002.49101.x PMID: 12366438
  78. Bhatia KP, Münchau A, Thompson PD, et al. Generalised muscular weakness after botulinum toxin injections for dystonia: A report of three cases. J Neurol Neurosurg Psychiatry 1999; 67(1): 90-3. doi: 10.1136/jnnp.67.1.90 PMID: 10369829
  79. Wilson F. Botulinum toxin: A risks overcome by proper technique. Cosmetic Surg Times 2001; 12
  80. Botox: Highlights of Prescribing Information. 2022. Available from: https://www.rxabbvie.com/pdf/botox_pi.pdf
  81. Update of safety review of onabotulinumtoxinA (marketed as Botox/Botox Cosmetic), AbobotulinumtoxinA (marketed as Dysport) and RimabotulinumtoxinB (marketed as Myobloc). 2017. Available from: https://web.archive.org/web/20171115034159/https:/www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174959.htm
  82. Rimawi BH. Botulism in pregnancy - A clinical approach to diagnosis and management. J Matern Fetal Neonatal Med 2019; 32(18): 3125-32. doi: 10.1080/14767058.2018.1457641 PMID: 29577785
  83. Brin MF, Kirby RS, Slavotinek A, et al. Pregnancy outcomes following exposure to onabotulinumtoxinA. Pharmacoepidemiol Drug Saf 2016; 25(2): 179-87. doi: 10.1002/pds.3920 PMID: 26635276
  84. Newman WJ, Davis TL, Padaliya BB, et al. Botulinum toxin type A therapy during pregnancy. Mov Disord 2004; 19(11): 1384-5. doi: 10.1002/mds.20205 PMID: 15389988
  85. Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D 2015; 15(1): 1-9. doi: 10.1007/s40268-014-0077-1 PMID: 25559581
  86. Smirnoff L. Safety of OnabotulinumtoxinA in the management of chronic migraine in pregnancy. Front Pain Res 2022; 3: 967580. doi: 10.3389/fpain.2022.967580 PMID: 36061414
  87. Altunal Ç, Şahiner İT. Relationship between psychological symptoms and self-esteem levels before and after stomach botox treatment. Med Sci Monit 2023; 29: e939618. doi: 10.12659/MSM.939618 PMID: 37029484
  88. Bensen GP, Rutherford CC, Gardner TB. Systemic botulism toxicity caused by pyloric botox injection to treat gastroparesis. Case Rep Gastroenterol 2020; 14(2): 373-6. doi: 10.1159/000508854 PMID: 32884513
  89. Eriksson SE, Zheng P, Morton S, et al. Predictors of favorable outcome after pyloroplasty for gastroparesis: should response to pyloric dilation or Botox injection be used as a marker of surgical outcome? Surg Endosc 2023; 37(6): 4360-9. doi: 10.1007/s00464-023-09882-2 PMID: 36749378
  90. Ezaizi Y, Hasan B, Manini ML, Absah I. Intrapyloric botulinum toxin a injection for gastroparesis and functional upper gastrointestinal symptoms in children: Mayo clinic experience, review of the literature, and meta-analysis. Paediatr Drugs 2022; 24(5): 539-45. doi: 10.1007/s40272-022-00518-x PMID: 35768647
  91. Yen YA, Wang CC, Sung WW, et al. Intragastric injection of botulinum toxin A for weight loss: A systematic review and meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2022; 37(6): 983-92. doi: 10.1111/jgh.15847 PMID: 35383416
  92. Cangemi DJ, Lacy BE. Gastroparesis. Curr Opin Gastroenterol 2021; 37(6): 596-601. doi: 10.1097/MOG.0000000000000782 PMID: 34560721
  93. Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol 2008; 103(2): 416-23. doi: 10.1111/j.1572-0241.2007.01676.x PMID: 18070232
  94. Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. Clinical guideline: Management of gastroparesis. Am J Gastroenterol 2013; 108(1): 18-37. doi: 10.1038/ajg.2012.373 PMID: 23147521
  95. Arts J, Holvoet L, Caenepeel P, et al. Clinical trial: A randomized- controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther 2007; 26(9): 1251-8. doi: 10.1111/j.1365-2036.2007.03467.x PMID: 17944739
  96. Bach K, Simman R. The multispecialty toxin: A literature review of botulinum toxin. Plast Reconstr Surg Glob Open 2022; 10(4): e4228. doi: 10.1097/GOX.0000000000004228 PMID: 35402123
  97. Ukleja A, Tandon K, Shah K, Alvarez A. Endoscopic botox injections in therapy of refractory gastroparesis. World J Gastrointest Endosc 2015; 7(8): 790-8. doi: 10.4253/wjge.v7.i8.790 PMID: 26191343
  98. Rao AK, Sobel J, Chatham-Stephens K, Luquez C. Clinical guidelines for diagnosis and treatment of botulism, 2021. MMWR Recomm Rep 2021; 70(2): 1-30. doi: 10.15585/mmwr.rr7002a1 PMID: 33956777
  99. Parrera GS, Astacio H, Tunga P, Anderson DM, Hall CL, Richardson JS. Use of botulism antitoxin heptavalent (A, B, C, D, E, F, G)-(equine) (BAT®) in clinical study subjects and patients: A 15-year systematic safety review. Toxins (Basel) 2021; 14(1): 19. doi: 10.3390/toxins14010019 PMID: 35050996
  100. Shi DY, Lu JS, Mao YY, et al. Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs. Appl Microbiol Biotechnol 2023; 107(10): 3205-16. doi: 10.1007/s00253-023-12515-2 PMID: 37058230
  101. Anderson DM, Kumar VR, Arper DL, Kruger E, Bilir SP, Richardson JS. Cost savings associated with timely treatment of botulism with botulism antitoxin heptavalent product. PLoS One 2019; 14(11): e0224700. doi: 10.1371/journal.pone.0224700 PMID: 31697731
  102. Chalk CH, Benstead TJ, Pound JD, Keezer MR. Medical treatment for botulism. Cochrane Libr 2019; 4(4): CD008123. doi: 10.1002/14651858.CD008123.pub4 PMID: 30993666

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers